Alzheimer's disease (AD) has a progressive neurodegenerative pathology
with severe economic and social impact. There is currently no cure, although
cholinesterase inhibitors provide effective temporary relief of symptoms in some
patients. Nowadays, drug research and development are based on the cholinergic
hypothesis that supports the cognition improvement by regulation of the synthesis and
release of acetylcholine in the brain. There are only five commercial medicines
Donepezil, galantamine, memantine, rivastigmine, tacrine approved for treatment of
AD. Natural products have played an important alternative role in the research for new
acetylcholinesterase inhibitors, as exemplified through the discovery of galantamine.
AD is the dementia associated with aging, which initially targets memory and
progressively destroys the functions of the brain, as the neocortex suffers neuronal,
synaptic, and dendritic losses. The whole phenomena proliferate due to deposition of
amyloid plaques. The goal of the present work is to analyse the search on drugs for the
treatment and prevention of AD in the light of Acetyl cholinesterase activity. It is based
on systematisation of the data on biochemical and structural similarities in the
interaction between physiologically active compounds and their biological targets
related to the development of such pathologies.
Keywords: Acetylcholinesterase, acetyl cholinesterase and disease dementia,
adamantyl derivative, Alzheimer’s disease, 7-Azaindole, butyrylcholinesterase,
dementia of natural product, drugs available for senile, enzyme and dementia,
enzyme inhibition and alzheimer, galantamine, loss of memory and plaque
formation, mechanism of dementia drugs, microtubule, napthyl derivative,
nitrophenacyl derivative, physostigmine, regulation of memory by effective
bioactive agents, synthetic drugs and alzheimer disease, synthesis, solving the
mystery of dementia.
